ULTRAVIOLET-VISIBLE

REFERENCE SPECTRA
The ultraviolet-visible reference spectra presented here were obtained by the use of double-
beam spectrophotometers with sample solutions prepared as specified in the individual
monographs. The horizontal axis indicates the wavelength (nm) and the vertical axis indi-
cates the absorbance.
JP XVII Ultraviolet-visible Reference Spectra 2225

Acebutolol Hydrochloride

Acemetacin

Acetohexamide 1

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2226 Ultraviolet-visible Reference Spectra JP XVII

Acetohexamide 2

Aciclovir

Aclarubicin Hydrochloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2227

Acrinol Hydrate

Actinomycin D

Adrenaline

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2228 Ultraviolet-visible Reference Spectra JP XVII

Afloqualone

Alimemazine Tartrate

Allopurinol

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2229

Alminoprofen

Alprazolam

Alprenolol Hydrochloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2230 Ultraviolet-visible Reference Spectra JP XVII

Alprostadil

Alprostadil Alfadex

Ambenonium Chloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2231

Amiodarone Hydrochloride

Amitriptyline Hydrochloride

Amlexanox

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2232 Ultraviolet-visible Reference Spectra JP XVII

Amlodipine Besilate

Amosulalol Hydrochloride

Amoxapine

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2233

Amphotericin B

Ampiroxicam

Aprindine Hydrochloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2234 Ultraviolet-visible Reference Spectra JP XVII

Argatroban Hydrate

Arotinolol Hydrochloride

Aspoxicillin Hydrate

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2235

Atenolol

Atorvastatin Calcium Hydrate

Azathioprine

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2236 Ultraviolet-visible Reference Spectra JP XVII

Azelastine Hydrochloride

Azelnidipine

Aztreonam

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2237

Bacampicillin Hydrochloride

Baclofen

Bamethan Sulfate

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2238 Ultraviolet-visible Reference Spectra JP XVII

Benidipine Hydrochloride

Benserazide Hydrochloride

Benzalkonium Chloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2239

Benzbromarone

Benzethonium Chloride

Benzylpenicillin Benzathine Hydrate

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2240 Ultraviolet-visible Reference Spectra JP XVII

Benzylpenicillin Potassium

Bepotastine Besilate

Beraprost Sodium

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2241

Berberine Chloride Hydrate

Berberine Tannate

Betahistine Mesilate

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2242 Ultraviolet-visible Reference Spectra JP XVII

Betamethasone

Betamethasone Dipropionate

Betamipron

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2243

Betaxolol Hydrochloride

Bezafibrate

Bifonazole

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2244 Ultraviolet-visible Reference Spectra JP XVII

Biperiden Hydrochloride

Bisacodyl

Bisoprolol Fumarate

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2245

Bleomycin Hydrochloride

Bleomycin Sulfate

Bromazepam

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2246 Ultraviolet-visible Reference Spectra JP XVII

Bromhexine Hydrochloride

Bromocriptine Mesilate

Brotizolam

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2247

Bucumolol Hydrochloride

Bufetolol Hydrochloride

Buformin Hydrochloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2248 Ultraviolet-visible Reference Spectra JP XVII

Bumetanide

Bupivacaine Hydrochloride Hydrate

Bupranolol Hydrochloride

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
JP XVII Ultraviolet-visible Reference Spectra 2249

Buprenorphine Hydrochloride

Butenafine Hydrochloride

Butropium Bromide 1

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)
2250 Ultraviolet-visible Reference Spectra JP XVII

Butropium Bromide 2

Cadralazine

Calcitonin Salmon

The JP Drugs are to be tested according to the provisions given in the pertinent monographs, General Notices, General Rules for Crude Drugs,
General Rules for Preparations, and General Tests for their conformity to the Japanese Pharmacopoeia. (See the General Notices 5.)